Suppr超能文献

97例环孢素时代系统性红斑狼疮患者及匹配对照的肾移植结果

Outcome of renal transplantation in ninety-seven cyclosporine-era patients with systemic lupus erythematosus and matched controls.

作者信息

Stone J H, Amend W J, Criswell L A

机构信息

Johns Hopkins University, Baltimore, Maryland 21205, USA.

出版信息

Arthritis Rheum. 1998 Aug;41(8):1438-45. doi: 10.1002/1529-0131(199808)41:8<1438::AID-ART14>3.0.CO;2-A.

Abstract

OBJECTIVE

To evaluate the effectiveness of renal transplantation in systemic lupus erythematosus (SLE).

METHODS

A total of 97 SLE patients who underwent renal transplantation between January 1984 and September 1996 were selected for study and were matched with a group of non-SLE controls (1 control for each SLE patient) who also received transplants during that period. SLE patients and controls were matched on 6 covariates: age, sex, race, type of allograft (cadaveric versus living-related), number of previous transplants, and year of transplantation. All study subjects received either cyclosporine or FK-506/tacrolimus as part of their immunosuppressive regimen. In a rigorous medical records review, the status of each allograft and the cause of each graft loss was determined. Using a stratified Cox proportional hazards model, the transplantation outcomes of the SLE patients were compared with those of the controls. The effects of 9 individual variables on transplantation outcomes were also examined, and the statistically significant variables were compared in a stratified, multivariate Cox proportional hazards model.

RESULTS

The control group included patients with 20 different causes of end-stage renal disease (ESRD). The mean followup times for the SLE patients and controls were 323 weeks and 320 weeks, respectively. During the followup period, 52 SLE patients and 37 controls lost their allografts. The 1-, 2-, 5-, and 10-year allograft survival probabilities for the 2 groups (SLE versus controls) were as follows: 81.7% versus 88.2% (1-year); 74.7% versus 84.4% (2-year); 45.9% versus 75.0% (5-year); and 18.5% versus 34.8% (10-year). In the multivariate model, the relative hazard of allograft loss associated with SLE as the cause of ESRD was 2.1 (95% confidence interval 1.06-4.06, P = 0.0328). The total number of HLA mismatches, smoking status, and delayed allograft function were also associated with allograft loss in the multivariate model.

CONCLUSION

Compared with matched controls, renal transplant patients with SLE had inferior transplantation outcomes, with more than twice the risk of allograft loss.

摘要

目的

评估肾移植治疗系统性红斑狼疮(SLE)的有效性。

方法

选取1984年1月至1996年9月期间接受肾移植的97例SLE患者进行研究,并与一组同期接受移植的非SLE对照者(每例SLE患者匹配1例对照者)进行匹配。SLE患者和对照者在6个协变量上进行匹配:年龄、性别、种族、同种异体移植物类型(尸体供肾与亲属活体供肾)、既往移植次数以及移植年份。所有研究对象均接受环孢素或FK - 506/他克莫司作为免疫抑制方案的一部分。通过严格审查医疗记录,确定每个同种异体移植物的状态以及每次移植物丢失的原因。使用分层Cox比例风险模型,将SLE患者的移植结果与对照者进行比较。还检查了9个个体变量对移植结果的影响,并在分层多变量Cox比例风险模型中对具有统计学意义的变量进行比较。

结果

对照组包括患有20种不同终末期肾病(ESRD)病因的患者。SLE患者和对照者的平均随访时间分别为323周和320周。在随访期间,52例SLE患者和37例对照者失去了他们的同种异体移植物。两组(SLE组与对照组)1年、2年、5年和10年的同种异体移植物存活概率如下:81.7%对88.2%(1年);74.7%对84.4%(2年);45.9%对75.0%(5年);18.5%对34.8%(10年)。在多变量模型中,作为ESRD病因的SLE相关的同种异体移植物丢失的相对风险为2.1(95%置信区间1.06 - 4.06,P = 0.0328)。在多变量模型中,HLA错配总数、吸烟状况和移植肾功能延迟也与同种异体移植物丢失有关。

结论

与匹配的对照者相比,SLE肾移植患者的移植结果较差,同种异体移植物丢失风险高出两倍多。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验